FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to a protein complex agonist IL-15, consisting of soluble fusion protein (I) and soluble fusion protein (II), where fused protein (I) is IL-15 (L52C) with SEQ ID NO: 2, and fused protein (II) is selected from IL-15Rα-ECD (S40C)-Fc with SEQ ID NO: 5, Fc-IL-15Rα-ECD (S40C) with SEQ ID NO: 6, IL-15Rα-Sushi + (S40C) -Fc with SEQ ID NO: 7 or Fc-IL-15Rα-sushi + (S40C) with SEQ ID NO: 8, and can be used in medicine.
EFFECT: obtained protein complex is used for effective treatment IL-15-mediated diseases.
10 cl, 11 dwg, 7 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION BASED ON IL-15 PROTEIN COMPLEX AND APPLICATIONS THEREOF | 2018 |
|
RU2749342C1 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| HETERODIMERIC FC-FUSED PROTEINS IL15/IL15Rα | 2017 |
|
RU2779938C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| SCLEROSTIN ANTIBODY, ITS ANTIGEN-BINDING FRAGMENT AND MEDICAL APPLICATION | 2016 |
|
RU2716101C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION | 2019 |
|
RU2753282C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
